First-line EXL01 With Nivolumab and FOLFOX for PD-L1 CPS ≥5 Metastatic Gastric Cancer (BIG)

Gut Microbiome Intervention With EXL01 in Combination With Nivolumab and FOLFOX as First-line Treatment for Patients With PD-L1 CPS ≥5 Metastatic Gastric Cancer: A Randomized GERCOR Phase II Study (BIG)

This is a randomized non-comparative, multicenter phase II study in patients with PD-L1 PD-L1 combined positive score (CPS) ≥5 advanced gastric cancer to evaluate the efficacy and safety of nivolumab and FOLFOX in combination with EXL01 as first-line treatment.

After signing the informed consent form, and upon confirmation of the patient's eligibility, patients will be randomized in a 2:1 ratio to either the nivolumab and FOLFOX plus EXL01 arm (experimental) or the nivolumab and FOLFOX arm (control). In both arms, treatment will be given until PD, unacceptable toxicity or for a maximum of 24 months (52 cycles).

Study Overview

• Status: Recruiting
• Conditions: Gastric Cancer
• Intervention / Treatment: Drug: Nivolumab; Drug: FOLFOX regimen; Biological: EXL01

Detailed Description

The primary objective of the study is to assess the objective response rate (ORR) at 4 months (based on Response Evaluation Criteria in Solid Tumor [RECIST] criteria v1.1) of patients with PD-L1 CPS ≥ 5 advanced gastric cancer treated by EXL01 plus nivolumab and FOLFOX as first-line treatment.

With a randomization ratio of 2:1 it will be necessary to randomize 40 patients in the control arm, 80 patients in the experimental arm and so a total of 120 evaluable patients in the study. Randomization will be stratified by PD-L1 expression level, center, and prior gastrectomy.

In the experimental arm, the primary analysis will be on modified intent-to-treat (mITT) population. Confirmative analysis will be conducted firstly in the ITT population and secondly, in the Per Protocol (PP). Analyses of safety will be conducted in safety population.

The Kaplan-Meier method will be used to estimate time to event endpoints and described using the median and event-free rates over time with CI.

• Study Type: Interventional
• Enrollment (Estimated): 120
• Phase: Phase 2

Contacts and Locations

• Study Contact: Name: Marie-Line GARCIA LARNICOL, MD; Phone Number: +33 (01) 40 29 85 04; Email: marie-line.garcia-larnicol@gercor.com.fr

Study Locations

• France
  • Angers, France
    • Not yet recruiting
    • Institut de Cancerologie de l'Ouest Paul Papin
    • Contact: Sandrine HIRET, MD
  • Avignon, France
    • Recruiting
    • Clinique Sainte Catherine
    • Contact: Clémence TOULLEC, MD
  • Besançon, France
    • Recruiting
    • Centre Hospitalier Universitaire Jean MINJOZ
    • Contact: Angélique VIENOT, MD
  • Bordeaux, France
    • Not yet recruiting
    • Institut Bergonie
    • Contact: Simon PERNOT, MD
  • Brest, France
    • Not yet recruiting
    • Centre Hospitalier Universitaire Morvan
    • Contact: Estelle Dhamelincourt, MD
  • Caen, France
    • Not yet recruiting
    • Centre François Baclesse
    • Contact: Aurélie PARZY, MD
  • Cholet, France
    • Recruiting
    • Centre Hospitalier de Cholet
    • Contact: Thonas CENTRE HOSPITALIER DE CHOLET, MD
  • Clermont-Ferrand, France
    • Not yet recruiting
    • Centre Hospitalier Universitaire Clermont Ferrand - Site Estaing
    • Contact: Marine JARY, MD
  • Créteil, France
    • Not yet recruiting
    • Centre Hospitalier Henri Mondor
    • Contact: Charlotte FENIOUX, MD
  • Dijon, France
    • Recruiting
    • Centre Georges François Leclerc
    • Contact: François GHIRINGHELLI, MD
  • La Tronche, France
    • Not yet recruiting
    • Centre Hospitalier Universitaire Grenoble Alpes - Site Nord - Hopital Michallon
    • Contact: Gael ROTH, MD
  • Lille, France
    • Recruiting
    • Centre Hospitalier Universitaire De Lille
    • Contact: Anthony TURPIN, MD
  • Lyon, France
    • Not yet recruiting
    • Hôpital Privé Jean Mermoz
    • Contact: Pascal Artru, MD
  • Lyon, France
    • Recruiting
    • Hôpital Léon Berard
    • Contact: Clélia COUTZAC, MD
  • Marseille, France
    • Not yet recruiting
    • Hôpital la Timone
    • Contact: Laétitia DAHAN, MD
  • Montpellier, France
    • Not yet recruiting
    • Centre Hospitalier Universitaire de Montpellier
    • Contact: Eric ASSENAT, MD
  • Nantes, France
    • Not yet recruiting
    • Centre Hospitalier Universitaire Nantes - Hopital Hotel Dieu
    • Contact: Tamara MATYSIAK-BUDNIK, MD
  • Nice, France
    • Recruiting
    • Centre Antoine Lacassagne
    • Contact: Ludovic EVESQUE, MD
  • Paris, France
    • Not yet recruiting
    • Institut Curie
    • Contact: Cindy NEUZILLET, MD
  • Paris, France
    • Not yet recruiting
    • Institut Mutualiste Montsouris
    • Contact: Emilie SOULARUE, MD
  • Paris, France
    • Not yet recruiting
    • Groupe Hospitalier Diaconesses Croix Saint-Simon
    • Contact: Olivier DUBREUIL, MD
  • Paris, France
    • Recruiting
    • Hôpital Saint Antoine
    • Contact: Romain COHEN, MD
  • Paris, France
    • Not yet recruiting
    • Hopital Europeen Georges Pompidou
    • Contact: Aziz Zaanan, MD
  • Paris, France
    • Not yet recruiting
    • Hôpital Saint-Louis
    • Contact: Thomas APARICIO, MD
  • Paris, France
    • Not yet recruiting
    • Institut Gustave Roussy
    • Contact: Cristina SMOLENSCHI, MD
  • Paris, France
    • Not yet recruiting
    • Centre Hospitalier Cochin
    • Contact: Anna PELLAT, MD
  • Poitiers, France
    • Recruiting
    • Centre Hospitalier Universitaire de Poitiers - Hopital de La Miletrie
    • Contact: David TOUGERON, MD
  • Reims, France
    • Not yet recruiting
    • Institut Jean Godinot
    • Contact: Damien BOTSEN, MD
  • Reims, France
    • Recruiting
    • Centre Hospitalier Universitaire Reims Hopital Robert Debre
    • Contact: Olivier BOUCHE, MD
  • Rennes, France
    • Not yet recruiting
    • Centre Hospitalier Universitaire de Rennes
    • Contact: Astrid LIEVRE, MD
  • Saint-Mandé, France
    • Not yet recruiting
    • Hopital d'Instruction des Armees BEGIN
    • Contact: Julie LAVOLE, MD
  • St-Malo, France
    • Not yet recruiting
    • Centre Hospitalier Saint-Malo
    • Contact: Romain DESGRIPPES, MD
  • Strasbourg, France
    • Not yet recruiting
    • Institut de cancérologie Strasbourg Europe
    • Contact: Meher BEN ABDELGHANI, MD
  • Tours, France
    • Not yet recruiting
    • Centre Hospitalier Universitaire Tours - Hopital Trousseau
    • Contact: Elise DOUARD TOURNET, MD
  • Vandœuvre-lès-Nancy, France
    • Not yet recruiting
    • CENTRE HOSPITALIER REGIONAL UNIVERSITAIRE DE NANCY Site Brabois
    • Contact: Marie MULLER, MD
  • Villejuif, France
    • Recruiting
    • Hôpital Paul Brousse
    • Contact: Pascal Hammel, MD
  • Villeurbanne, France
    • Not yet recruiting
    • Medipole Hopital Mutualiste Lyon-Villeurbanne
    • Contact: Mathieu SARABI, MD

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

1. Patients must have dated and signed an approved written informed consent form. This must be obtained before the performance of any protocol-related procedures that are not part of normal patient care.

2. Patients must be willing and able to comply with scheduled visits, treatment schedule, laboratory tests and other requirements of the study,

   Target Population

3. Inoperable, advanced, or metastatic gastric cancer or gastroesophageal junction or distal esophageal carcinoma and histologically confirmed predominant adenocarcinoma,
4. Expression of PD-L1 with a combined positive score (PD-L1 CPS) ≥5, Note: information must be available at the time of inclusion, the examination will be performed locally in the center and secondarily confirmed centrally,
5. No prior systemic cancer treatment given as primary therapy for advanced nonresectable or metastatic disease, Note: if patient received neoadjuvant/adjuvant therapy, this therapy should be completed at least 6 months prior to the diagnosis of metastatic or recurrent disease is made. Palliative radiotherapy is allowed and must be completed 2 weeks prior to randomization,
6. At least one measurable lesion as assessed by computed tomography (CT)-scan or magnetic resonance imaging (MRI) according to Response Evaluation Criteria in Solid Tumors (RECIST) v 1.1 and feasibility of repeated radiological assessments; radiographic tumor assessment should be performed within 28 days prior to randomization,
7. Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 or 1,

8. Adequate hematologic and end-organ function, defined by the following laboratory test results, obtained within 14 days prior to randomization of study treatment:

   1. White blood cell ≥ 2000/μL;
   2. Neutrophils ≥ 2000/μL;
   3. Platelets ≥ 100.000/μL;
   4. Hemoglobin ≥ 9.0 g/dL;
   5. Serum albumin ≥ 30 g/L;
   6. Serum creatinine level ≤ 150 μM and calculated creatinine clearance (Cockcroft-Gault) > 50 mL/minute,
   7. Total bilirubin ≤ 1.5 x upper normal limit (ULN);
   8. Alanine aminotransferase (ALT) ≤ 3.0 x ULN (or ≤ 5.0 x ULN if liver metastases are present);
   9. Aspartame aminotransferase (AST) ≤ 3.0 x ULN (or ≤ 5.0 x ULN if liver metastases are present);
   10. Potassium ≥ 1.0 x lower limit of normal (LLN),
   11. Magnesium ≥ 1.0 x LLN,
   12. Calcium ≥ 1.0 x LLN,
9. Baseline-corrected QT interval ≤ 450 msec for males and ≤ 470 msec for females,
10. Availability of a representative tumor tissue specimen for exploratory translational research; tumor tissue samples, either formalin- fixed paraffin-embedded (FFPE) tissue block or unstained tumor tissue sections (minimum of 20 positively charged slides) from primary or metastatic site must be submitted to the central laboratory,

11. Registration in a national health care system (PUMa-Protection Universelle Maladie included.

    Age and reproductive status

12. Age ≥ 18 years,
13. Women must not be pregnant, breastfeeding, or expecting to conceive during the study,

14. Reproductive status:

    1. Women of childbearing potential (WOCBP) must have a negative serum pregnancy test within 72 hours prior to the start of study drug,
    2. WOCBP must agree to use an adequate method of contraception or birth control for the duration of study treatment and 5 months (nivolumab), 9 months (oxaliplatin), 6 months (5-FU) or at least 1 month (EXL01) of the patient's last dose of the study drug,
    3. Males who are fertile and sexually active with WOCBP must agree to follow instructions for method(s) of contraception for the duration of study treatment and 6 months (nivolumab, oxaliplatin, or 5-FU) or at least 1 month (EXL01) after the last dose of study treatment. In addition, males must be willing to refrain from sperm donation during this time,

Exclusion Criteria:

Target Disease Exceptions

1. Known HER-2 positive status or unknown HER-2 status before inclusion,
2. Active brain metastases or known history of leptomeningeal carcinomatosis,

3. Ascites, which cannot be controlled with appropriate interventions,

   Exclusion criteria related to medical history and concurrent disease

4. Prior malignancy active within the previous 3 years except for locally curable cancers that have been apparently cured, such as basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the prostate, cervix, or breast,
5. Active, known, or suspected autoimmune disease; type I diabetes mellitus, hypothyroidism only requiring hormone replacement, skin disorders (such as vitiligo, psoriasis, or alopecia) not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger are permitted,
6. Interstitial lung disease that is symptomatic or may interfere with the detection or management of suspected treatment-related pulmonary toxicity,
7. Prior treatment with an anti-PD(L)1, anti-LAG-3, or anti-CTLA-4 antibody, or any other antibody or drug specifically targeting T-cell co- stimulation or immune checkpoint pathways, including prior therapy with anti-tumor vaccines or other immuno-stimulatory antitumor agents,
8. Condition requiring systemic treatment with either corticosteroids (>10 mg daily prednisone equivalent) or other immunosuppressive medications within 14 days (2 weeks) of randomization. Inhaled or topical steroids, and adrenal replacement steroid doses >10 mg daily prednisone equivalent, are permitted prior to randomization in the absence of active autoimmune disease,
9. Persistence of toxicity (The National Cancer Institute Common Terminology Criteria for Adverse Event [NCI CTCAE] v 5.0) grade >1 related to prior anticancer treatments,
10. Major surgery within 28 days (4 weeks) prior to first dose of study treatment, Note: Participants who had surgery >4 weeks prior to screening must have recovered adequately from any toxicity and/or complications from the surgery or trauma prior to starting study intervention.

11. Concomitant unplanned antitumor therapy (e.g., chemotherapy, molecular targeted therapy, radiotherapy, immunotherapy),

    Exclusion criteria related to EXL01

12. GI obstruction, poor oral intake, or difficulty in taking oral medication or difficulties in swallowing; nasogastric tubes are not permitted,
13. Known GI malabsorption,
14. Is currently participating in or has participated in a study with an investigational compound within 28 days prior to the first dose of study treatment, Note: Participants who have entered the follow-up phase of an investigational study may participate so long as it has been at least 3 months since the last dose of the previous investigational agent,
15. Prior allogeneic bone marrow transplantation or prior solid organ transplantation,
16. Fecal microbiota transplant within 3 months prior to screening, Note: Patients must have recovered adequately from the toxicity and/or complications from the treatment prior to starting study intervention.

17. Current probiotics administration, or planned probiotics administration during treatment course is not allowed, Note: The following therapies should be avoided during the study; however, they are not prohibited if, in the assessment of the

    Investigator, they are required for clinical management:

    • Nonsteroidal anti-inflammatories,
    • Antacids,
    • Proton-pump inhibitors.
18. Excessive alcohol intake: moderate consumption, defined as no more than 1 drink per day for women and no more than 2 drinks per day for men, is permitted,
19. Known allergy and/or hypersensitivity to any component or excipients of study treatments (nivolumab, EXL01), any other live pro- biotherapeutic product, and/or to soybean or soy-containing products,
20. Known history or newly diagnosed GI parasitic infection within 3 months prior to screening, Note: Patients must have recovered adequately from the toxicity and/or complications from the treatment prior to starting study intervention,

21. Active inflammatory intestinal disease (Crohn disease, Hemorrhagic recto-colitis, coeliac disease) or any serious chronic intestinal disease with uncontrolled diarrhea, or other inflammatory disease requiring anti-inflammatory medications (according to exclusion criteria n°8),

    Exclusion criteria related to chemotherapy

22. Active or chronic hepatitis B virus (HBV), hepatitis C virus (HCV) and/or human immunodeficiency virus infection (HIV 1/2 antibodies).

    Participants are eligible if they:

    • Have controlled HCV load defined as undetectable hepatitis C RNA by polymerase chain reaction either spontaneously or in response to a successful prior course of anti-hepatitis C therapy,
    • Have received HBV vaccination with only anti-HBs positivity and no clinical signs of hepatitis,
    • Are HBV surface antigen (HBsAg)- and anti- Hepatitis B core antibody (HBc)+ (i.e., those who have cleared HBV after infection),

    • Are HBsAg+ with chronic HBV infection (lasting 6 months or longer) and meet conditions below:

      • HBV DNA viral load <100 IU/mL,
      • Have normal transaminase values, or, if liver metastases are present, abnormal transaminases, with a result of AST/ALT <3 × ULN, which are not attributable to HBV infection,
      • Start or maintain antiviral treatment if clinically indicated as per the investigator,
23. Any (attenuated) live vaccine use within 28 days (4 weeks) prior to randomization, while in the study; live vaccines include, but are not limited to, the following: yellow fever, varicella, shingles, measles, mumps, rubella, tuberculosis, rotavirus, influenza,
24. Ongoing or concomitant use of the antiviral drug sorivudine or its chemically related analogs, such as brivudine,
25. Dihydropyrimidine dehydrogenase deficiency (DPD; uracilemia dosage >16 ng/ml), Uracilemia dosing results must be available before inclusion,
26. Any condition that, in the opinion of the investigator, would interfere with evaluation of the investigational product or interpretation of the patient's safety or study results,
27. Known peripheral sensory neuropathy with functional impairment according exclusion criteria n°9) prior to first treatment, according to the Summary of product characteristics (SmPC) of oxaliplatin,
28. Known potentially serious infection, according to the SmPC of 5-FU
29. Has clinically significant active heart disease or myocardial infarction within 6 months given the cardiotoxicity of 5-FU, according to the SmPC of 5-FU,

30. Known history of hypersensitivity to 5-FU, oxaliplatin, or leucovorin, or to any of their excipients, according to the SmPCs of these products.

    Exclusion criteria related to geographical, social, and legal issues

31. Impossibility of submitting to the medical follow-up of the study for geographical, social, or psychiatric illness,
32. Patient under a legal protection regime (guardianship, curatorship, judicial safeguard) or administrative decision or incapable of giving his/her consent.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Nivolumab Combined With FOLFOX and EXL01; Nivolumab 240 mg IV q2w and FOLFOX q2w plus EXL01 orally once daily	Drug: Nivolumab; Nivolumab 240 mg IV; every 2 weeks; Other Names: Opdivo; Drug: FOLFOX regimen; Oxaliplatin 85 mg/m², leucovorin 400 mg/m², bolus of 5-FU 400 mg/m², continuous 5-FU 2400/m² in 46 hours; every 2 weeks; Other Names: Leucovorin, fluorouracil, and oxaliplatin; Biological: EXL01; Orally 1 capsule/day, starting on day 1 of each FOLFOX/nivolumab treatment.
Active Comparator: Nivolumab and FOLFOX; Nivolumab 240 mg IV q2w and FOLFOX q2w	Drug: Nivolumab; Nivolumab 240 mg IV; every 2 weeks; Other Names: Opdivo; Drug: FOLFOX regimen; Oxaliplatin 85 mg/m², leucovorin 400 mg/m², bolus of 5-FU 400 mg/m², continuous 5-FU 2400/m² in 46 hours; every 2 weeks; Other Names: Leucovorin, fluorouracil, and oxaliplatin

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Objective response rate (ORR) at 4 months	ORR measured at 4 months post randomization in patients with PD-L1 CPS ≥5 advanced gastric cancer treated by first-line EXL01 plus nivolumab and FOLFOX. ORR at 4 months is defined as the number of patients with a CR or PR evaluated by RECIST v 1.1 criteria divided by the number of patients evaluable.	At 4 months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
2-year and 3-year OS	2-year and 3-year OS rate of nivolumab plus FOLFOX with or without EXL01	At 2 years and 3 years
1-year and 2-year PFS	1-year and 2-year PFS rates per RECIST v 1.1 and iRECIST (immune RECIST) criteria with nivolumab plus FOLFOX with or without EXL01	At 1 year and at 2 years
Overall survival (OS)	OS with nivolumab plus FOLFOX with or without EXL01. OS is defined as the time between the date of randomization and the date of death from any cause.	Maximum 3 years after randomization
Progression-free survival (PFS)	PFS per RECIST v 1.1 and iRECIST of nivolumab plus FOLFOX with or without EXL01. PFS is defined as the time from randomization to the date of the first documented PD determined by the Investigator assessment by RECIST 1.1 or death due to any cause, whichever occurs first.	Maximum 3 years after randomization
Assessment of safety profile	Safety of nivolumab plus FOLFOX with or without EXL01. Safety will be measured by the incidence of Adverse Events (AEs), Serious AEs (SAEs), deaths, laboratory abnormalities, and specific immune-related AEs (hepatitis, colitis, myositis, endocrinopathies).	Maximum 3 years after randomization
Duration of response (DoR)	DoR with FOLFOX plus nivolumab with or without EXL01. DoR is defined as the time between the date of first documented response (complete response [CR] or partial response [PR]) to the date of the first disease progression, per RECIST 1.1 or death due to any cause, whichever occurs first. For patients who neither progress nor die, the duration of objective response will be censored at the same time they were censored for the primary definition of PFS.	Maximum 3 years after randomization
Objective response rate (ORR)	ORR per RECIST v 1.1 criteria nivolumab plus FOLFOX with or without EXL01. ORR is defined as the number of patients with the best overall response (BOR) of CR or PR divided by the number of measurable patients with target lesion at baseline. BOR is defined as the best response designation, recorded between the date of randomization and the date of objectively documented progression (per RECIST 1.1) or the date of subsequent anti-cancer therapy, whichever occurs first.	Maximum 3 years after randomization

Collaborators and Investigators

• Sponsor: GERCOR - Multidisciplinary Oncology Cooperative Group
• Investigators: Principal Investigator: Romain Cohen, MD, Saint-Antoine Hospital

Study record dates

Study Major Dates

• Study Start (Actual): April 16, 2024
• Primary Completion (Estimated): September 1, 2027
• Study Completion (Estimated): April 1, 2029

Study Registration Dates

• First Submitted: January 31, 2024
• First Submitted That Met QC Criteria: February 2, 2024
• First Posted (Actual): February 12, 2024

Study Record Updates

• Last Update Posted (Actual): September 22, 2025
• Last Update Submitted That Met QC Criteria: September 16, 2025
• Last Verified: September 1, 2025

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Neoplasms by Site; Neoplasms; Gastrointestinal Neoplasms; Digestive System Neoplasms; Digestive System Diseases; Gastrointestinal Diseases; Stomach Diseases; Stomach Neoplasms; Amino Acids, Peptides, and Proteins; Proteins; Organic Chemicals; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Enzymes and Coenzymes; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal; Antibodies; Immunoglobulins; Immunoproteins; Blood Proteins; Serum Globulins; Globulins; Coordination Complexes; Pyrimidines; Formyltetrahydrofolates; Tetrahydrofolates; Folic Acid; Pterins; Pteridines; Uracil; Pyrimidinones; Coenzymes; Oxaliplatin; Nivolumab; Fluorouracil; Leucovorin; Folfox protocol
• Other Study ID Numbers: BIG G-122 PRODIGE 94

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No